- Home
- BCSF vs SNDX Comparison
BCSF vs SNDX Comparison
Compare BCSF & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- SNDX
- Stock Information
- Founded
- BCSF 2015
- SNDX 2005
- Country
- BCSF United States
- SNDX United States
- Employees
- BCSF N/A
- SNDX N/A
- Industry
- BCSF Finance/Investors Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- SNDX Health Care
- Exchange
- BCSF Nasdaq
- SNDX Nasdaq
- Market Cap
- BCSF 983.4M
- SNDX 1.1B
- IPO Year
- BCSF 2018
- SNDX 2016
- Fundamental
- Price
- BCSF $15.68
- SNDX $17.04
- Analyst Decision
- BCSF Buy
- SNDX Strong Buy
- Analyst Count
- BCSF 2
- SNDX 10
- Target Price
- BCSF $16.50
- SNDX $37.40
- AVG Volume (30 Days)
- BCSF 237.0K
- SNDX 2.4M
- Earning Date
- BCSF 11-04-2025
- SNDX 11-04-2025
- Dividend Yield
- BCSF 11.48%
- SNDX N/A
- EPS Growth
- BCSF N/A
- SNDX N/A
- EPS
- BCSF 1.66
- SNDX N/A
- Revenue
- BCSF $283,687,000.00
- SNDX $77,933,000.00
- Revenue This Year
- BCSF N/A
- SNDX $585.73
- Revenue Next Year
- BCSF N/A
- SNDX $94.17
- P/E Ratio
- BCSF $9.43
- SNDX N/A
- Revenue Growth
- BCSF N/A
- SNDX 2126.66
- 52 Week Low
- BCSF $13.20
- SNDX $8.58
- 52 Week High
- BCSF $19.21
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- BCSF 59.14
- SNDX 77.37
- Support Level
- BCSF $15.53
- SNDX $15.81
- Resistance Level
- BCSF $15.75
- SNDX $16.89
- Average True Range (ATR)
- BCSF 0.20
- SNDX 0.74
- MACD
- BCSF 0.03
- SNDX -0.06
- Stochastic Oscillator
- BCSF 79.11
- SNDX 89.74
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.